PHARMACY

Mylan partners with Sarah Jessica Parker on anaphylaxis initiative

BY Gina Acosta

HERTFORDSHIRE, England and PITTSBURGH — Mylan is teaming up with actress and mom Sarah Jessica Parker on a national campaign to educate the public about the serious and unpredictable nature of anaphylaxis.

The company is unveiling an initiative called Anaphylaxis: For Reel. Through this initiative, Mylan, along with Parker and leading advocacy organizations, aims to inspire greater understanding about the risks of anaphylaxis. The campaign encourages young filmmakers and their families to make their voices heard by creating and submitting short, educational films about the realities of managing severe allergies. Parker, whose son has allergies to peanuts and hazelnuts, is joining this initiative to share her story and personal connection to this life-threatening health condition that affects families nationwide.

"With Anaphylaxis: For Reel, I hope to help empower other families affected by severe allergies to share their personal stories," Parker said. "Like every family, we have our own story. We learned about our son's food allergies only after he experienced anaphylaxis – and I still vividly remember how scary that day was for all of us. Since then, we've come to understand just how serious the risks of anaphylaxis are – and how crucial it is to take proactive steps to manage his severe allergies."

Anaphylaxis is a significant health issue in the U.S., with up to 43 million people at risk, including children affected by food allergies, estimated at one in 13. Every six minutes, on average, food-related anaphylaxis sends someone in the U.S. to the emergency department. 

"Anaphylaxis is very unpredictable – symptoms can vary from person to person, and reactions can be mild one time and life-threatening the next," said Dr. Hemant Sharma, clinical chief of the division of allergy and immunology at Children's National Health System in Washington, D.C. "Our goal with this initiative is to have the real-life, everyday stories of those who deal with life-threatening allergies firsthand shine a spotlight on the urgent need to increase education about the importance of being ready to respond if anaphylaxis occurs."

A panel, including Dr. Sharma and leading advocacy organization members, will come together to select up to five films to be featured at a premiere event in New York City this fall with Parker and posted on Anaphylaxis101.com. Films can be submitted on Anaphylaxis101.com through July 11. Films will be evaluated based upon creativity, originality and adherence to submission guidelines.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

CVS Health Research Institute: Home infusion both economically and clinically viable

BY Michael Johnsen
WOONSOCKET, R.I. – A new study by the CVS Health Research Institute found that home infusion care is safe, clinically effective and improves quality of life while reducing health care costs when compared to infusion care delivered in a hospital or clinic. 
 
The findings underscore the value of home infusion services – where medication is delivered intravenously in a patient's home – for the health care system, including patients and payers. The study was published in Healthcare: The Journal of Delivery Science and Innovation.
 
"As the U.S. health care payment system shifts from volume to value, we are focused on identifying new approaches to health service delivery that provide better care and improve patient outcomes while lowering costs," stated Troyen Brennan, study author and chief medical officer CVS Health. "Our research shows that home infusion care is a promising model that is both cost- and clinically-effective and is overwhelmingly preferred by patients when intravenous therapy is required." 
 
Researchers conducted a systematic review of existing peer-reviewed research evaluating infusion care for several conditions, including cystic fibrosis, antibiotics following orthopedic surgery and several cancers requiring infused chemotherapies. Researchers compared measures of quality, safety, clinical outcomes, quality of life and costs of home infusion services to those provided in medical settings. The research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting. In addition, patients overwhelmingly preferred receiving their infusion therapies at home, reporting fewer disruptions in personal schedules and responsibilities. The costs associated with home infusion were also consistently lower than services provided in a health care facility, with savings ranging between $1,928 and $2,974 per course of treatment.  
 
"At CVS Health, we provide important home infusion services to patients through Coram, which is just one of the ways we are expanding our clinical delivery model and helping to move important health services to lower cost sites of care," added Alan Lotvin, EVP CVS Specialty. "In fact, our patients report high satisfaction with our Coram home infusion services, citing convenience and comfort as key elements that improved their overall experience."
 
 
 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Reuters: Pfizer approaches Medivation about potential takeover

BY Gina Acosta

Pfizer has approached Medivation about a possible purchase of the company, raising the possibility of a bid rivaling a $9.3 billion offer by Sanofi SA, Reuters reported on Wednesday. (Reuters)

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?